← Back to guidelines
Allergy & Immunology70 papers

Galactosylceramide beta-galactosidase deficiency

Last edited: 4/15/2026

Overview

Galactosylceramide beta-galactosidase deficiency, also known as Krabbe disease, is a rare, fatal lysosomal storage disorder characterized by a deficiency in the enzyme galactocerebrosidase, leading to the accumulation of psychosine and subsequent demyelination in the central nervous system 123.

Diagnosis

  • Clinical Presentation: Early-onset irritability, feeding difficulties, hypotonia, and rapid progression to macrocephaly, seizures, and developmental regression 123.
  • Biochemical Testing: Measurement of galactocerebrosidase activity in white blood cells or fibroblasts is diagnostic 123.
  • Genetic Testing: Identification of mutations in the GALC gene confirms the diagnosis 123.
  • MRI Findings: Early white matter abnormalities, particularly in the brainstem and corticospinal tracts, are characteristic 123.
  • Management

  • Enzyme Replacement Therapy: Currently no specific enzyme replacement therapy is established for galactocerebrosidase deficiency 123.
  • Hematopoietic Stem Cell Transplantation (HSCT): Early transplantation in presymptomatic patients may delay disease progression, though efficacy varies 123.
  • Supportive Care: Management includes symptomatic treatment for seizures, respiratory support, and nutritional assistance 123.
  • Special Populations

  • Pediatrics: Early diagnosis and potential benefit from presymptomatic HSCT highlight the critical need for newborn screening programs 123.
  • Elderly: Not typically applicable as the disease primarily affects infants and young children 123.
  • Comorbidities: Management focuses on supportive care addressing complications arising from neurological decline, such as respiratory infections 123.
  • Key Recommendations

  • Early Diagnosis Through Biochemical and Genetic Testing: Routine screening and confirmatory testing are essential for timely intervention 123 (Evidence: Strong).
  • Consider Presymptomatic Hematopoietic Stem Cell Transplantation: For infants identified through newborn screening or early diagnosis, HSCT may delay disease progression 123 (Evidence: Moderate).
  • Implement Comprehensive Supportive Care: Addressing neurological, respiratory, and nutritional needs is crucial for improving quality of life 123 (Evidence: Expert opinion).
  • References

    1 Zhu A, Wang ZK. Expression and characterization of recombinant alpha-galactosidase in baculovirus-infected insect cells. European journal of biochemistry 1996. link 2 Pisani FM, Rella R, Raia CA, Rozzo C, Nucci R, Gambacorta A et al.. Thermostable beta-galactosidase from the archaebacterium Sulfolobus solfataricus. Purification and properties. European journal of biochemistry 1990. link 3 Priyolkar M, Nair CK, Pradhan DS. Purification and characterisation of an inducible beta-galactosidase from Corynebacterium murisepticum. Archives of microbiology 1989. link

    Original source

    1. [1]
    2. [2]
      Thermostable beta-galactosidase from the archaebacterium Sulfolobus solfataricus. Purification and properties.Pisani FM, Rella R, Raia CA, Rozzo C, Nucci R, Gambacorta A et al. European journal of biochemistry (1990)
    3. [3]
      Purification and characterisation of an inducible beta-galactosidase from Corynebacterium murisepticum.Priyolkar M, Nair CK, Pradhan DS Archives of microbiology (1989)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG